209 related articles for article (PubMed ID: 16529013)
41. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
42. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha.
Bacher U; Hochhaus A; Berger U; Hiddemann W; Hehlmann R; Haferlach T; Schoch C
Leukemia; 2005 Mar; 19(3):460-3. PubMed ID: 15625554
[No Abstract] [Full Text] [Related]
43. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
Medeiros BC; Chun K; Kamel-Reid S; Lipton J
Am J Hematol; 2007 Aug; 82(8):758-60. PubMed ID: 17301975
[TBL] [Abstract][Full Text] [Related]
44. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?
O'Shea D; Crotty G; Carroll P; Conneally E; McCann S; Neat MJ
Br J Haematol; 2004 Nov; 127(3):367-9. PubMed ID: 15491304
[No Abstract] [Full Text] [Related]
45. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
Andrikovics H; Nahajevszky S; Szilvási A; Bors A; Adám E; Kozma A; Kajtár B; Barta A; Poros A; Tordai A
Hematol Oncol; 2007 Sep; 25(3):143-7. PubMed ID: 17530620
[TBL] [Abstract][Full Text] [Related]
46. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Kantarjian H; O'Brien S; Talpaz M; Borthakur G; Ravandi F; Faderl S; Verstovsek S; Rios MB; Shan J; Giles F; Cortes J
Cancer; 2007 Apr; 109(8):1556-60. PubMed ID: 17342766
[TBL] [Abstract][Full Text] [Related]
47. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
48. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
[TBL] [Abstract][Full Text] [Related]
49. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
50. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
Szych CM; Liesveld JL; Iqbal MA; Li L; Siebert S; Asmus C; O'Malley J; Lee A; Wang N
Cancer Genet Cytogenet; 2007 Apr; 174(2):132-7. PubMed ID: 17452255
[TBL] [Abstract][Full Text] [Related]
51. Imatinib mesylate: A designer drug.
Panigrahi I; Naithani R
J Assoc Physicians India; 2006 Mar; 54():203-6. PubMed ID: 16800347
[TBL] [Abstract][Full Text] [Related]
52. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
Wassmann B; Gökbuget N; Scheuring UJ; Binckebanck A; Reutzel R; Gschaidmeier H; Hoelzer D; Ottmann OG;
Ann Hematol; 2003 Nov; 82(11):716-20. PubMed ID: 14648032
[No Abstract] [Full Text] [Related]
53. [Major molecular response to imatinib in a patient with acute mixed lineage leukemia expressing a novel BCR/ABL transcript].
Liu HX; Cao XY; Tong CR; Wu T; Wang T; Fan QZ; Wu P; Zhang X; Cai P; Zhu P
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):220-3. PubMed ID: 19552835
[TBL] [Abstract][Full Text] [Related]
54. Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.
Georgiou G; Efthymiou A; Vardounioti I; Boutsikas G; Angelopoulou MK; Vassilakopoulos TP; Kyrtsonis MC; Plata E; Tofas P; Bitsani A; Bartzi V; Pessach I; Dimou M; Panayiotidis P
Leukemia; 2012 Apr; 26(4):824-6. PubMed ID: 21986839
[No Abstract] [Full Text] [Related]
55. Characterization of Ph-negative abnormal clones emerging during imatinib therapy.
Abruzzese E; Gozzetti A; Galimberti S; Trawinska MM; Caravita T; Siniscalchi A; Cervetti G; Mauriello A; Coletta AM; De Fabritiis P
Cancer; 2007 Jun; 109(12):2466-72. PubMed ID: 17503437
[TBL] [Abstract][Full Text] [Related]
56. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
57. Additional rearrangements affecting the derivative chromosome 9 involved in the standard Philadelphia translocation after imatinib therapy in a patient with chronic myeloid leukemia.
Wang HP; Chen ZM; Lou JY; Xu H; Yu YB; Jin J
Cancer Genet Cytogenet; 2008 Apr; 182(1):63-4. PubMed ID: 18328955
[No Abstract] [Full Text] [Related]
58. Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
Tiribelli M; Marin L; Calistri E; Geromin A; Damiani D; Fanin R
Bone Marrow Transplant; 2004 Nov; 34(9):827-8. PubMed ID: 15334052
[No Abstract] [Full Text] [Related]
59. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
Chee YL; Vickers MA; Stevenson D; Holyoake TL; Culligan DJ
Leukemia; 2003 Mar; 17(3):634-5. PubMed ID: 12646955
[No Abstract] [Full Text] [Related]
60. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Herens C; Baron F; Croisiau C; Tassin F; Bours V
Cancer Genet Cytogenet; 2003 Nov; 147(1):78-80. PubMed ID: 14580776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
